16 results about "Clavulanic acid" patented technology

The invention discloses application of a transcriptional regulation factor SCLAVp0126 in regulation of the fermentation yield of clavulanic acid of a strain, the fermentation yield of clavulanic acid of a mutant strain can be remarkably increased by knocking out the transcriptional regulation factor SCLAVp0126 in a streptomyces clavuliformis genome, and the application has a good industrial application prospect.

This invention provides a novel nebulization suspension comprising amoxicillin and clavulanate for the effective treatment of pneumonia. The formulation is specifically designed for pulmonary delivery, offering several advantages over traditional oral antibiotics. Key features include mucoadhesive properties that enhance drug retention 5 in the lungs, sustained release characteristics for prolonged therapeutic action, and potential biofilm disruption to combat antibiotic resistance. This localized delivery approach aims to minimize systemic side effects, improve treatment efficacy, and address the growing challenge of antibiotic resistance in pneumonia.

The invention provides a fermentation method of clavulanic acid, and relates to the technical field of biological pharmacy. The method comprises the following steps: inoculating streptomyces clavuliformis into a shake flask seed culture medium, and carrying out shake flask seed culture; inoculating the cultured shake flask seeds to a seed culture medium, and performing seed tank culture; the method comprises the following steps: inoculating a strain into a fermentation culture medium, culturing in a fermentation tank, centrifugally separating the obtained fermentation liquid, and separating and purifying the supernatant liquid to obtain clavulanic acid; wherein in the 20th hour of fermentation, glycerol is supplemented; supplementing the mixed supplementary material at the 40th hour of fermentation; the mixed supplementary material comprises L-glutamic acid, magnesium chloride, dipotassium phosphate, glacial acetic acid and potassium hydroxide. According to the method disclosed by the invention, the glycerol and the mixed supplementary material are supplemented at a specific time point in the fermentation process of the clavulanic acid, so that the fine regulation and control of the fermentation process are realized, and the technical effect of remarkably improving the titer of the clavulanic acid is achieved.

The invention discloses a combined treatment method and system for potassium clavulanate fermentation waste bacterial liquid and wastewater. According to the method, through the whole-process collaborative design of pretreatment, anaerobic biochemical treatment, biogas desulfurization, sulfur recovery, anaerobic ammonia oxidation, deep biochemical treatment, energy recovery and sludge treatment, the degradation efficiency is improved by adopting ultrasonic wall breaking; the anaerobic ammonia oxidation technology is used for treating low-carbon-nitrogen-ratio and high-ammonia-nitrogen wastewater, the recycled biogas is used for energy supply, elemental sulfur generated by desulfurization replaces an exogenous carbon source, and real-time parameter optimization is achieved in cooperation with a PLC intelligent regulation and control system. The system breaks through a traditional mushroom residue-wastewater step-by-step treatment mode, realizes in-situ harmless treatment and resource utilization of dangerous mushroom residues, solves the problems of high treatment cost, serious secondary pollution, carbon-nitrogen imbalance and the like in the prior art, has the advantages of low energy consumption, low cost, high pollutant removal rate, remarkable resource recovery benefit and the like, and has a wide application prospect. The method is suitable for co-treatment of high-concentration organic wastewater and hazardous waste mushroom dregs in the fermentation pharmaceutical industry.

The application discloses a kind of adolescent autism intestinal microorganism marker and application thereof, belong to the field of biological medicine.The microorganism marker includes one or more of Ruminococcus gnavus, Streptococcus thermophilus, Streptococcus salivarius, Butte's intestinal bacillus, pet big anaerobic clavulanic acid bacteria and Prevotella pittmanniae.The application provides a kind of product (such as kit), including detection reagent for detecting the relative abundance of the microorganism marker.The product provided by the application has good feasibility and accuracy, and can effectively evaluate whether adolescent has the risk of autism, provides a new tool for clinical diagnosis.

The utility model is suitable for the technical field of decolorizing and concentrating equipment, and provides a clavulanic acid decolorizing and concentrating device which comprises a decolorizing and concentrating kettle, the kettle cover is fixed at the top of the decolorizing and concentrating kettle through a bolt; the electric push rod is fixed at the central position of the top of the kettle cover through a bolt; the stainless steel thermometer probe is fixed at the output end of the electric push rod; the infrared liquid level sensor is fixed at one side, close to the stainless steel thermometer probe, of the bottom of the kettle cover through a screw; the filling pipe is fixed at one side, close to the electric push rod, of the top of the kettle cover through a bolt; the clavulanic acid solution is guided by the guide cover, so that the clavulanic acid solution is fully refrigerated to reduce the temperature, the clavulanic acid solution is ensured to be in a low-temperature state when being decolorized and concentrated in the decolorizing and concentrating kettle, the influence of temperature rise of the clavulanic acid solution on decolorizing and concentrating is avoided, and the product quality is improved.

The invention belongs to the technical field of biological medicines, and discloses a method for preparing clavulanic acid by a biological fermentation method. The method comprises the following steps: inoculating a seed bacterial liquid of streptomyces clavuliformis into a fermentation culture medium for fermentation culture, and collecting a fermentation product to obtain clavulanic acid, wherein in the fermentation culture process, an amylase enzymolysis solution is supplemented, the total sugar concentration range of fermentation liquor is maintained to be 6 g / L-12 g / L, and the amylase enzymolysis solution is obtained by performing enzymolysis and liquefaction on starch through alpha-amylase. By adopting the method, the fermentation titer can be improved, and the production cost of the clavulanic acid can be reduced.

This invention relates to a compound antibacterial agent and its application in open plant tissue culture. The active ingredients of the compound antibacterial agent include rifampin, kasugamycin, ticarcillin sodium clavulanic acid, and tetrachloroisophthalonitrile. The compound antibacterial agent can synergistically inhibit Agrobacterium rhizogenes or Rhodotorula glutinis, contaminating bacteria that are easily generated during plant tissue culture.

The present invention relates to an application of a combined preparation of cefathiamidine and clavulanic acid in the treatment of tuberculosis. Cefathiamidine and clavulanic acid are used in combination to significantly improve the activity against Mycobacterium tuberculosis. It is verified by in vitro experiments that the β-lactamase inhibitor clavulanic acid significantly improves the anti-tuberculosis effect of cefathiamidine. The combined preparation shows significant advantages in inhibiting the growth of Mycobacterium tuberculosis and has a strong inhibitory effect on drug-resistant strains. At the same time, the combined preparation shows lower cytotoxicity in in vitro experiments and shows better safety. In addition, the combined preparation has potential application prospects in the treatment of drug-resistant tuberculosis and can effectively supplement existing tuberculosis treatment regimens.

The invention discloses an application of an MSR1 inhibitor in preparation of an anti-tumor immunopotentiator. The MSR1 inhibitor is composed of doxylamine, trafenotide, dexrazoxane and clavulanic acid. The invention discloses application of an MSR1 inhibitor combined with an immune checkpoint inhibitor in preparation of a medicine for treating solid tumors. The MSR1 inhibitor disclosed by the invention is used as an anti-tumor immunopotentiator and is combined with an immune checkpoint inhibitor to treat solid tumors, so that the curative effect of tumor immunotherapy can be improved. The MSR1 inhibitor can induce tumor-related macrophages to be differentiated into anti-tumor subtypes, anti-tumor immunity is driven through phagocytosis and generation of cell factors, and a new method is provided for improving the curative effect of tumor immunotherapy.

The invention relates to an application of a cefathiamidine and clavulanic acid combined preparation in tuberculosis treatment, cefathiamidine and clavulanic acid are combined for use, and the activity of resisting mycobacterium tuberculosis is remarkably improved. In-vitro experiments prove that the beta-lactamase inhibitor clavulanic acid remarkably improves the antituberculous effect of cefathiamidine, and the combined preparation shows remarkable advantages in the aspect of inhibiting the growth of mycobacterium tuberculosis and has a relatively strong inhibiting effect on drug-resistant strains. Meanwhile, the combined preparation shows relatively low cytotoxicity in an in-vitro experiment, and shows relatively good safety. In addition, the combined preparation has a potential application prospect in treatment of drug-resistant tuberculosis, and can effectively supplement the existing tuberculosis treatment scheme.

The invention relates to a recombinant engineering bacterium for efficiently producing corac acid (CA) and application of the recombinant engineering bacterium. A key gene synthesized by CA is edited, and rcsA and rcsB are constructed; galU, galE, ugD, manB, manC, gmd and fcl genes, an acetic acid pathway gene, a cofactor regeneration related gene and a CA synthesis cluster related gene; through overexpression in two modes of plasmid or genome integration, a recombinant engineering bacterium for high-yield production of CA is obtained. The provided recombinant engineering bacterium provides a basis for large-scale production.

The utility model relates to the technical field of chemical equipment, concretely relates to a clavulanic acid purification concentration system to solve the problem of big water consumption and high energy consumption in prior art. The system includes a first ceramic membrane separation unit, a first shunt control unit, a second ultrafiltration membrane separation unit, a second shunt control unit, a third nanofiltration membrane separation unit and a third shunt control unit, and the system is also provided with a three-stage circulation loop, and the flow direction of the concentrated liquid and dialysis liquid output by the membrane separation units at all stages is controlled through the shunt control units at all stages and the multistage circulation loop to improve the purification efficiency, reduce energy consumption and production cost, and ensure the product quality stability.

The invention discloses a pharmaceutical composition for inhibiting CRE and application, and relates to the technical field of drug research and development, and the key points of the technical scheme are as follows: the effect of aztreonam combined with four beta-lactamase inhibitors (avibactam, clavulanic acid, tazobactam and sulbactam) on 77 CRE isolates in Shenzhen children hospitals is evaluated. It is found that most of CRE isolates, resistant to aztreonam, in CRE isolates collected in Shenzhen children hospitals carry MBL and other beta-lactamase genes at the same time. And aztreonam / avibactam has good antibacterial activity on all the tested strains. For isolates which carry MBL genes but do not have AmpC enzyme coding genes, aztreonam / clavulanic acid can be used as a more economical and potential combination therapy regimen than aztreonam / avibactam, but is not suitable for CRE isolates carrying AmpC enzyme genes.

The invention discloses a clavulanic acid fermentation preparation method, and belongs to the technical field of biological medicines. Comprising the following steps: preparing a fermentation culture medium by adopting a composite nitrogen source instead of a single nitrogen source, inoculating a streptomyces clavuliformis seed solution to the fermentation culture medium for culturing, supplementing different material supplementing modes according to different fermentation stages in the fermentation process, and collecting a fermentation product to obtain clavulanic acid, a nitrogen source in the fermentation culture medium comprises 10-20g / L of soybean cake powder, 5-10g / L of peanut protein powder and 2-5g / L of peptone; the supplementary materials comprise supplementary materials A, B, C and D; the supplementary material A comprises glycerol, the supplementary material B comprises corn oil, the supplementary material C comprises proteolysis liquid, and the supplementary material D comprises threonine and glutamic acid. According to the method, the clavulanic acid fermentation cost can be reduced, the viscosity in the clavulanic acid fermentation process is reduced, the oxygen dissolving condition in the process is improved, the mass transfer efficiency of fermentation liquor is improved, thallus aging is delayed, the fermentation time is prolonged, the fermentation titer is improved, generation of waste such as fungus residues is reduced, the economic value is increased, and the environmental protection pressure is relieved.

The utility model discloses a clavulanic acid hypha treatment device which comprises a treatment tank and a steam generator, a first steam conveying pipe is connected between the treatment tank and the steam generator, a dehydration structure is connected to the treatment tank, a supporting frame is connected to the dehydration structure, and a five-effect evaporator is connected to the dehydration structure; when the device is used, clavulanic acid and hypha mixed liquid and lime milk can be placed in the treatment tank and are mixed for coagulation and precipitation, and the coagulation and precipitation speed can be increased by adding steam into the steam generator in the process, so that other impurities such as protein and inorganic salt in the clavulanic acid and hypha mixed liquid can be separated, and the clavulanic acid and hypha mixed liquid can be recycled. The method comprises the following steps: firstly, extracting and purifying clavulanic acid, then conveying a mixed solution subjected to coagulation and precipitation to a filter press for solid-liquid separation, and concentrating the separated liquid by using a five-effect evaporator, so that target components such as clavulanic acid and the like are concentrated, and subsequent extraction and purification steps are facilitated.